Table 2.

Genotype calling of paired clinical samples using GCP* of msp1 and msp2.

Patient ID	Time after treatment	Genotype called by the software compared to hr 0	Msp1 Confidence % relative to hr 0	Msp2 Confidence % relative to hr 0
HL 1204	hr 0	HL1204	99.53	99.41
	hr 18	HL1204	82.17	82.95
	hr 45	HL1204	59.52	55.65
HL 1205	hr 0	HL1205	98.59	90.75
	hr 15	Variation	<50	<50
	hr 36	HL1205	70.27	Negative
HL 1209	hr 0	HL1209	99.77	98.72
	hr 13	HL1209	56.35	69.63
	hr 37	HL1209	57.80	<50
HL 1210	hr 0	HL1210	94.75	98.52
	hr 15	HL1210	73.23	74.35
	hr 40	Negative	NA	NA
HL 1211	hr 0	HL1211	99.83	95.89
	hr 24	HL1211	65.63	88.57
	hr 48	HL1211	77.51	94.24

All clinical samples after treatment had the same genotype compared to their corresponding samples before treatment (hr 0) samples with a GCP of more than 50%. Exceptions are HL1205 and HL1209, where both had a post-treatment genotype different from the pre-treatment in one or more loci. A second time-point after treatment was included for comparison purposes and in order to further evaluate the performance of msp1 and msp2 HRM genotyping for low parasitaemia samples. *GCP, Genotype Confidence Percentage, percentage of similarity of post-treatment sample to its corresponding pre-treatment sample.